Cargando…
Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study)
BACKGROURD: H. pylori-associated gastric cancer is the first cancer-related death in Bhutan. Effective regimen for H. pylori eradication is essential to reduce risk of developing gastric cancer. Clarithromycin is not widely used in this limited resource country. Aim of this study was to evaluate pro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445957/ https://www.ncbi.nlm.nih.gov/pubmed/32334478 http://dx.doi.org/10.31557/APJCP.2020.21.4.1109 |
_version_ | 1783574086275825664 |
---|---|
author | Vilaichone, Ratha-Korn Aumpan, Natsuda Ratanachu-ek, Thawee Gumnarai, Pornpen Uchid, Tomohisa Tshering, Lotay Mahachai, Varocha Yamaoka, Yoshio |
author_facet | Vilaichone, Ratha-Korn Aumpan, Natsuda Ratanachu-ek, Thawee Gumnarai, Pornpen Uchid, Tomohisa Tshering, Lotay Mahachai, Varocha Yamaoka, Yoshio |
author_sort | Vilaichone, Ratha-Korn |
collection | PubMed |
description | BACKGROURD: H. pylori-associated gastric cancer is the first cancer-related death in Bhutan. Effective regimen for H. pylori eradication is essential to reduce risk of developing gastric cancer. Clarithromycin is not widely used in this limited resource country. Aim of this study was to evaluate proper regimen and prevalence of antibiotic resistance pattern for H. pylori eradication in Bhutan. METHODS: Five hundred and forty-six patients underwent gastroscopy during GASTROCAMP between October 2014 and April 2015 in Bhutan and 77 patients were enrolled. Four gastric biopsies were obtained for rapid urease test, histopathology, H. pylori culture with Epsilometer test. All H. pylori-positive patients were randomized to receive either 7-day or 14-day of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily. RESULTS: Seventy-seven subjects were enrolled (54 females, 23 males, mean age = 45.4 years). Of 77 patients, 52 (67.5%) received 7-day regimen while 25 (32.5%) had 14-day regimen. Prevalence of H. pylori was 38.2%. Antibiotic resistance was 80.0% for metronidazole, 11.1% for levofloxacin and no resistance seen in amoxicillin, tetracycline and clarithromycin. Overall eradication rates of 7-day and 14-day regimens were 51.9% and 80.0%, p = 0.02. Female and age ≥40 years had significantly higher eradication rate when receiving 14-day compared to 7-day regimen (94.1% vs. 45.9%, OR = 18.82; 95% CI 2.26-157.02, p = 0.0007 and 86.7% vs. 50.0%, OR = 6.50; 95% CI 1.25-33.91, p = 0.02, respectively). CONCLUSIONS: Fourteen-day regimen might be an acceptable regimen for H. pylori eradication in limited resource area such as Bhutan. Female and age ≥40 years should receive longer duration of treatment. This 14-day regimen could at least reduce the risk of developing H. pylori-associated diseases especially peptic ulcer with complications and gastric cancer which lead to many deaths in Bhutan. |
format | Online Article Text |
id | pubmed-7445957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-74459572020-09-02 Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) Vilaichone, Ratha-Korn Aumpan, Natsuda Ratanachu-ek, Thawee Gumnarai, Pornpen Uchid, Tomohisa Tshering, Lotay Mahachai, Varocha Yamaoka, Yoshio Asian Pac J Cancer Prev Research Article BACKGROURD: H. pylori-associated gastric cancer is the first cancer-related death in Bhutan. Effective regimen for H. pylori eradication is essential to reduce risk of developing gastric cancer. Clarithromycin is not widely used in this limited resource country. Aim of this study was to evaluate proper regimen and prevalence of antibiotic resistance pattern for H. pylori eradication in Bhutan. METHODS: Five hundred and forty-six patients underwent gastroscopy during GASTROCAMP between October 2014 and April 2015 in Bhutan and 77 patients were enrolled. Four gastric biopsies were obtained for rapid urease test, histopathology, H. pylori culture with Epsilometer test. All H. pylori-positive patients were randomized to receive either 7-day or 14-day of 500 mg amoxicillin four times daily, 500 mg tetracycline four times daily, and 20 mg omeprazole twice daily. RESULTS: Seventy-seven subjects were enrolled (54 females, 23 males, mean age = 45.4 years). Of 77 patients, 52 (67.5%) received 7-day regimen while 25 (32.5%) had 14-day regimen. Prevalence of H. pylori was 38.2%. Antibiotic resistance was 80.0% for metronidazole, 11.1% for levofloxacin and no resistance seen in amoxicillin, tetracycline and clarithromycin. Overall eradication rates of 7-day and 14-day regimens were 51.9% and 80.0%, p = 0.02. Female and age ≥40 years had significantly higher eradication rate when receiving 14-day compared to 7-day regimen (94.1% vs. 45.9%, OR = 18.82; 95% CI 2.26-157.02, p = 0.0007 and 86.7% vs. 50.0%, OR = 6.50; 95% CI 1.25-33.91, p = 0.02, respectively). CONCLUSIONS: Fourteen-day regimen might be an acceptable regimen for H. pylori eradication in limited resource area such as Bhutan. Female and age ≥40 years should receive longer duration of treatment. This 14-day regimen could at least reduce the risk of developing H. pylori-associated diseases especially peptic ulcer with complications and gastric cancer which lead to many deaths in Bhutan. West Asia Organization for Cancer Prevention 2020-04 /pmc/articles/PMC7445957/ /pubmed/32334478 http://dx.doi.org/10.31557/APJCP.2020.21.4.1109 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Vilaichone, Ratha-Korn Aumpan, Natsuda Ratanachu-ek, Thawee Gumnarai, Pornpen Uchid, Tomohisa Tshering, Lotay Mahachai, Varocha Yamaoka, Yoshio Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) |
title | Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) |
title_full | Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) |
title_fullStr | Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) |
title_full_unstemmed | Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) |
title_short | Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study) |
title_sort | efficacy of omeprazole, tetracycline, and 4 times daily dosing of amoxicillin in helicobacter pylori eradication in limited resource area in bhutan: a prospective randomized trial (bhutan study) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445957/ https://www.ncbi.nlm.nih.gov/pubmed/32334478 http://dx.doi.org/10.31557/APJCP.2020.21.4.1109 |
work_keys_str_mv | AT vilaichonerathakorn efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT aumpannatsuda efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT ratanachuekthawee efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT gumnaraipornpen efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT uchidtomohisa efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT tsheringlotay efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT mahachaivarocha efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy AT yamaokayoshio efficacyofomeprazoletetracyclineand4timesdailydosingofamoxicillininhelicobacterpylorieradicationinlimitedresourceareainbhutanaprospectiverandomizedtrialbhutanstudy |